ATE292640T1 - Therapeutische verbindungen gegen eierstockkrebs - Google Patents

Therapeutische verbindungen gegen eierstockkrebs

Info

Publication number
ATE292640T1
ATE292640T1 AT01939696T AT01939696T ATE292640T1 AT E292640 T1 ATE292640 T1 AT E292640T1 AT 01939696 T AT01939696 T AT 01939696T AT 01939696 T AT01939696 T AT 01939696T AT E292640 T1 ATE292640 T1 AT E292640T1
Authority
AT
Austria
Prior art keywords
ovarian cancer
therapeutic compounds
compounds against
against ovarian
compounds
Prior art date
Application number
AT01939696T
Other languages
German (de)
English (en)
Inventor
Charles A Nicolette
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE292640T1 publication Critical patent/ATE292640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01939696T 2000-05-31 2001-05-30 Therapeutische verbindungen gegen eierstockkrebs ATE292640T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20938800P 2000-05-31 2000-05-31
US25700700P 2000-12-20 2000-12-20
PCT/US2001/017454 WO2001092306A2 (en) 2000-05-31 2001-05-30 Therapeutic compounds for ovarian cancer

Publications (1)

Publication Number Publication Date
ATE292640T1 true ATE292640T1 (de) 2005-04-15

Family

ID=26904120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01939696T ATE292640T1 (de) 2000-05-31 2001-05-30 Therapeutische verbindungen gegen eierstockkrebs

Country Status (8)

Country Link
US (2) US6737062B2 (enExample)
EP (1) EP1284997B1 (enExample)
JP (1) JP2004503217A (enExample)
AT (1) ATE292640T1 (enExample)
AU (1) AU2001265188A1 (enExample)
CA (1) CA2410895A1 (enExample)
DE (1) DE60109922D1 (enExample)
WO (1) WO2001092306A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410865A1 (en) * 2000-05-31 2001-12-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
EP1284997B1 (en) 2000-05-31 2005-04-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
EP1359937A4 (en) * 2001-02-14 2004-07-28 Genzyme Corp MODIFIED PEPTIDE LIGANDS
WO2002080845A2 (en) * 2001-04-04 2002-10-17 Genzyme Corporation Novel eps8 compounds for therapy and diagnosis and methods for using same
AU2002232563A1 (en) * 2001-12-05 2003-06-23 Genzyme Corporation Compounds for therapy and diagnosis and methods for using same
WO2003068925A2 (en) * 2002-02-11 2003-08-21 Mosca Joseph D Production of a protein delivery system for in vivo therapeutic treatment
JP2005191530A (ja) * 2003-12-03 2005-07-14 Sumitomo Electric Ind Ltd 発光装置
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
KR101530402B1 (ko) * 2007-10-09 2015-06-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (ｔｐｏｒａ)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5688657A (en) 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
EP0573608A1 (en) 1991-02-07 1993-12-15 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
JPH07101999A (ja) 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
DE19817946A1 (de) 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1290217A2 (en) 2000-02-04 2003-03-12 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1284997B1 (en) 2000-05-31 2005-04-06 Genzyme Corporation Therapeutic compounds for ovarian cancer

Also Published As

Publication number Publication date
WO2001092306A2 (en) 2001-12-06
EP1284997B1 (en) 2005-04-06
EP1284997A2 (en) 2003-02-26
US20030175252A1 (en) 2003-09-18
CA2410895A1 (en) 2001-12-06
US20050048068A1 (en) 2005-03-03
JP2004503217A (ja) 2004-02-05
DE60109922D1 (de) 2005-05-12
WO2001092306A3 (en) 2002-08-08
US6737062B2 (en) 2004-05-18
AU2001265188A1 (en) 2001-12-11

Similar Documents

Publication Publication Date Title
FI1897548T4 (fi) T-solujen säätely
MX338940B (es) Identificacion de epitopos ige novedosos.
IL214325A (en) Antibody against cmet, a drug that includes and uses it
EA200870130A1 (ru) Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
CR11399A (es) ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
TNSN07020A1 (en) Her2 antibody composition
CY1115147T1 (el) Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
EP2570137A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
PH12021552853A1 (en) Antibody drug conjugates
SI1572087T1 (sl) Protitelesa proti antigenu tmeff2 raka in njihovauporaba
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
AU2002359727A1 (en) Fused cyclic modulators of nuclear hormone receptor function
DE60238555D1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
ATE313560T1 (de) Therapeutische anti-cytomegalovirus verbindungen
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2001068677A3 (en) Derivatives of breast canacer antigen her-2 for therapeutical use
ATE297949T1 (de) Therapeutische verbindungen gegen eierstockkrebs
MX2025000487A (es) Anticuerpos anti-mesotelina
WO2001092307A3 (en) Therapeutic compounds for ovarian cancer
WO2002012272A8 (en) Therapeutic anti-melanoma compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties